Effects of artificial intelligence-SsupporTed Automated NutRiTional Intervention on LDL cholesterol Control in Patients with Familial Hypercholesterolaemia (iSTART-FH): protocol for a randomised controlled trial. Issue 12 (30th December 2021)

• Record Type: Journal Article
• Authors: Tada, Hayato; Okada, Hirofumi; Nomura, Akihiro; Usui, Soichiro; Sakata, Kenji; Hayashi, Kenshi; Fujino, Noboru; Yasugi, Ayaka; Takahara, Shizuko; Imai, Yasuhito; Takamura, Masayuki; Kawashiri, Masa-aki
• Is Part Of: BMJ open. Volume 11:Issue 12(2021)
• Publication Date: 2021-12-30
• Subjects: lipid disorders -- cardiology -- nutrition & dietetics -- risk management; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-053453
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Familial hypercholesterolaemia (FH) is an autosomal dominant inherited genetic disease that has an extremely elevated cardiovascular risk because of their significantly elevated low-density lipoprotein (LDL) cholesterol. Nutritional intervention is needed in improving LDL cholesterol control in patients with FH but requires a considerable burden in manpower. Artificial intelligence (AI)-supported and mobile-supported nutritional intervention using this technique may be an alternative approach to traditional nutritional counselling in person. This study aims to test the hypothesis that AI-supported nutritional counselling is more effective in reducing LDL cholesterol than the in-person, face-to-face method in terms of improving LDL cholesterol control in patients with FH. Methods and analysis: This is a single-centre, unblinded, cross-over, randomised controlled study comparing the efficacy of AI-supported automated nutrition therapy with that of conventional human nutrition counselling in patients with FH. Patients with FH are recruited and randomly assigned to AI-supported nutrition counselling (n=30) and to face-to face nutrition counselling (n=30). We are using an Asken, a mobile application that has been specially modified for this study so that it follows the recommendations by the Japan Atherosclerosis Society. We started patient recruitment on 1 September 2020, and is scheduled to continue until 31 December 2022. Ethics and dissemination: This study is being conducted in compliance with the Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and all other applicable laws and guidelines in Japan. The study protocol was approved by the Institutional Review Board of Kanazawa University on 13 April 2020 (IRB no. 2623-3); all recruited patients are required to provide written informed consent. We will disseminate the final results at international conferences and in a peer-reviewed journal. Trial registration number: UMIN000040198.